Matches in SemOpenAlex for { <https://semopenalex.org/work/W1569333935> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W1569333935 endingPage "7" @default.
- W1569333935 startingPage "1054" @default.
- W1569333935 abstract "Linomide is a p.o. active antiangiogenic agent that has been demonstrated to be effective in suppressing the in vivo growth of rat and human prostatic cancer xenografts. The present studies were conducted to determine whether the angiogenic molecules, vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) and basic fibroblast growth factor (bFGF) are expressed in vitro by DU-145, PC-3, TSU-PR1, and LnCaP human prostate cancer cell lines and whether Linomide inhibits the secretion of these angiogenic molecules. Additionally, two different androgen-responsive human prostatic cancer xenograft models (i.e., PC-82 and A-2) were used to determine whether androgen ablation-induced reduction in tumor growth is associated with a reduction in tumor VEGF and/or bFGF levels. These studies demonstrated that both VEGF and bFGF proteins are expressed to different degrees in the human prostatic cancer cell lines. The secretion of VEGF but not bFGF is up-regulated by hypoxia. Linomide is unable to inhibit either basal or hypoxia-induced secretion of VEGF. Linomide also has no effect on secreted bFGF levels. Castration inhibited tumor VEGF but had no effect on bFGF levels in both the androgen-responsive PC-82 and A-2 human prostatic cancers when grown in severe combined immunodeficient mice. When given in combination, castration potentiated the inhibition of tumor growth induced by Linomide alone. This potentiation is not due to a further inhibition in tumor VEGF levels induced by castration. Although both castration and Linomide inhibit angiogenesis, the former accomplishes it by inhibiting VEGF secretion, whereas the latter has multiple effects at several steps in the angiogenic process other than VEGF secretion. Based on their different but complementary mechanisms of action, simultaneous combination of androgen ablation with Linomide enhances the anti-prostatic cancer efficacy compared to either monotherapies alone and warrants testing in humans." @default.
- W1569333935 created "2016-06-24" @default.
- W1569333935 creator A5043265453 @default.
- W1569333935 creator A5067816762 @default.
- W1569333935 date "1997-03-15" @default.
- W1569333935 modified "2023-09-27" @default.
- W1569333935 title "Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers." @default.
- W1569333935 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9067270" @default.
- W1569333935 hasPublicationYear "1997" @default.
- W1569333935 type Work @default.
- W1569333935 sameAs 1569333935 @default.
- W1569333935 citedByCount "35" @default.
- W1569333935 countsByYear W15693339352013 @default.
- W1569333935 countsByYear W15693339352014 @default.
- W1569333935 countsByYear W15693339352015 @default.
- W1569333935 countsByYear W15693339352016 @default.
- W1569333935 countsByYear W15693339352017 @default.
- W1569333935 countsByYear W15693339352022 @default.
- W1569333935 crossrefType "journal-article" @default.
- W1569333935 hasAuthorship W1569333935A5043265453 @default.
- W1569333935 hasAuthorship W1569333935A5067816762 @default.
- W1569333935 hasConcept C121608353 @default.
- W1569333935 hasConcept C126322002 @default.
- W1569333935 hasConcept C134018914 @default.
- W1569333935 hasConcept C167734588 @default.
- W1569333935 hasConcept C170493617 @default.
- W1569333935 hasConcept C2775960820 @default.
- W1569333935 hasConcept C2777025900 @default.
- W1569333935 hasConcept C2777587049 @default.
- W1569333935 hasConcept C2777911890 @default.
- W1569333935 hasConcept C2779723316 @default.
- W1569333935 hasConcept C2780192828 @default.
- W1569333935 hasConcept C2780394083 @default.
- W1569333935 hasConcept C502942594 @default.
- W1569333935 hasConcept C71315377 @default.
- W1569333935 hasConcept C71924100 @default.
- W1569333935 hasConceptScore W1569333935C121608353 @default.
- W1569333935 hasConceptScore W1569333935C126322002 @default.
- W1569333935 hasConceptScore W1569333935C134018914 @default.
- W1569333935 hasConceptScore W1569333935C167734588 @default.
- W1569333935 hasConceptScore W1569333935C170493617 @default.
- W1569333935 hasConceptScore W1569333935C2775960820 @default.
- W1569333935 hasConceptScore W1569333935C2777025900 @default.
- W1569333935 hasConceptScore W1569333935C2777587049 @default.
- W1569333935 hasConceptScore W1569333935C2777911890 @default.
- W1569333935 hasConceptScore W1569333935C2779723316 @default.
- W1569333935 hasConceptScore W1569333935C2780192828 @default.
- W1569333935 hasConceptScore W1569333935C2780394083 @default.
- W1569333935 hasConceptScore W1569333935C502942594 @default.
- W1569333935 hasConceptScore W1569333935C71315377 @default.
- W1569333935 hasConceptScore W1569333935C71924100 @default.
- W1569333935 hasIssue "6" @default.
- W1569333935 hasLocation W15693339351 @default.
- W1569333935 hasOpenAccess W1569333935 @default.
- W1569333935 hasPrimaryLocation W15693339351 @default.
- W1569333935 hasRelatedWork W1569333935 @default.
- W1569333935 hasRelatedWork W1974613227 @default.
- W1569333935 hasRelatedWork W2074824105 @default.
- W1569333935 hasRelatedWork W2082788526 @default.
- W1569333935 hasRelatedWork W2085618049 @default.
- W1569333935 hasRelatedWork W2095264862 @default.
- W1569333935 hasRelatedWork W2097535434 @default.
- W1569333935 hasRelatedWork W2396486584 @default.
- W1569333935 hasRelatedWork W2887840215 @default.
- W1569333935 hasRelatedWork W3087152049 @default.
- W1569333935 hasVolume "57" @default.
- W1569333935 isParatext "false" @default.
- W1569333935 isRetracted "false" @default.
- W1569333935 magId "1569333935" @default.
- W1569333935 workType "article" @default.